share_log

Aethlon Medical | 8-K: Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Aethlon Medical | 8-K: Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Aethlon Medical | 8-K：Aethlon Medical公佈截至2024年9月30日的第二財季財務業績，並提供公司最新情況
美股SEC公告 ·  2024/11/14 05:21

Moomoo AI 已提取核心訊息

Aethlon Medical has achieved a significant milestone by enrolling its first two patients at Royal Adelaide Hospital in Australia for its Hemopurifier cancer trial. The company now has two Australian sites open for enrollment, with a third pending ethics approval. Additionally, they received ethics committee approval from Medanta Medicity Hospital in India for a similar trial.For Q2 FY2024 ended September 30, the company reported cash holdings of $6.9 million. Operating expenses decreased 9% to $2.9 million from $3.2 million YoY, primarily due to reduced professional fees of $600,000, partially offset by increased payroll expenses of $200,000 and general administrative costs of $100,000. Net loss improved to $2.8 million from $3.0 million in the prior year period.The company's Hemopurifier device, designed to combat cancer and viral infections, is undergoing safety and feasibility trials for patients with solid tumors who have failed anti-PD-1 antibody treatment. The study will examine the impact of 1-3 Hemopurifier treatments on extracellular vesicle concentrations and immune response to tumor cells.
Aethlon Medical has achieved a significant milestone by enrolling its first two patients at Royal Adelaide Hospital in Australia for its Hemopurifier cancer trial. The company now has two Australian sites open for enrollment, with a third pending ethics approval. Additionally, they received ethics committee approval from Medanta Medicity Hospital in India for a similar trial.For Q2 FY2024 ended September 30, the company reported cash holdings of $6.9 million. Operating expenses decreased 9% to $2.9 million from $3.2 million YoY, primarily due to reduced professional fees of $600,000, partially offset by increased payroll expenses of $200,000 and general administrative costs of $100,000. Net loss improved to $2.8 million from $3.0 million in the prior year period.The company's Hemopurifier device, designed to combat cancer and viral infections, is undergoing safety and feasibility trials for patients with solid tumors who have failed anti-PD-1 antibody treatment. The study will examine the impact of 1-3 Hemopurifier treatments on extracellular vesicle concentrations and immune response to tumor cells.
Aethlon Medical在澳洲皇家阿德萊德醫院招募了首兩名患者，已在其Hemopurifier癌症試驗中取得了重要里程碑。目前該公司在澳洲已開放兩個招募地點，第三個正在等待倫理批准。此外，他們還在印度Medanta Medicity醫院獲得了類似試驗的倫理委員會批准。截至2024財年第二季度（9月30日），該公司報告現金持有量爲690萬。營業費用同比下降9%，從320萬降至290萬，主要由於減少了60萬美元的專業費用，部分被20萬美元的薪資費用和10萬美元的一般行政費用所抵消。淨虧損從去年同期的300萬改善至280萬。該公司的Hemopurifier設備旨在對抗癌症和病毒感染，目前正在對已接受抗PD-1抗體治療失敗的實體腫瘤患者進行安全性和可行性試驗。該研究將考察1-3次Hemopurifier治療對細胞外囊泡濃度和腫瘤細胞免疫反應的影響。
Aethlon Medical在澳洲皇家阿德萊德醫院招募了首兩名患者，已在其Hemopurifier癌症試驗中取得了重要里程碑。目前該公司在澳洲已開放兩個招募地點，第三個正在等待倫理批准。此外，他們還在印度Medanta Medicity醫院獲得了類似試驗的倫理委員會批准。截至2024財年第二季度（9月30日），該公司報告現金持有量爲690萬。營業費用同比下降9%，從320萬降至290萬，主要由於減少了60萬美元的專業費用，部分被20萬美元的薪資費用和10萬美元的一般行政費用所抵消。淨虧損從去年同期的300萬改善至280萬。該公司的Hemopurifier設備旨在對抗癌症和病毒感染，目前正在對已接受抗PD-1抗體治療失敗的實體腫瘤患者進行安全性和可行性試驗。該研究將考察1-3次Hemopurifier治療對細胞外囊泡濃度和腫瘤細胞免疫反應的影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Pacific Biosciences of California
    PACB
    -- 1.850
    Avita Medical
    RCEL
    -- 10.570
    PAVmed
    PAVM
    -- 0.7900
    古特拉
    CUTR
    -- 0.481
    Lifeward
    LFWD
    -- 2.185
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！